Research Topics
| Erika von EuwSummaryCountry: Argentina Publications
| Collaborators
|
Detail Information
Publications
CTLA4 blockade increases Th17 cells in patients with metastatic melanomaErika von Euw
Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California, USA
J Transl Med 7:35. 2009..We studied the levels of this T cell subset in peripheral blood of patients treated with the anti-CTLA4 antibody tremelimumab since its major dose limiting toxicities are inflammatory and autoimmune in nature...
Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapyAntoni Ribas
Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA
J Immunother (1997) 27:354-67. 2004..Sequential CTLA4 blockade may enhance the immune activity of DC-based immunotherapy...
Immunosensitization with a Bcl-2 small molecule inhibitorJonathan Begley
Department of Surgery, University of California at Los Angeles, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
Cancer Immunol Immunother 58:699-708. 2009....- Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824Dan D Vo
Department of Medicine, Division of Hematology Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA
Cancer Res 69:8693-9. 2009..In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes... - Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanomaAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 15:6267-76. 2009..The combination was tested in a phase I clinical trial in patients with advanced melanoma... - Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)Lana Y Schumacher
Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles 90095, USA
J Immunol 176:4757-65. 2006..In conclusion, the proteasome inhibitor bortezomib can pharmacologically sensitize tumor cells to the lytic effects of DC-activated immune effector cells... - Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cellsJennifer A Wargo
Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA
Cancer Gene Ther 12:516-27. 2005..In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells... - Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanomaBradley R Straatsma
Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California 90095, USA
Am J Ophthalmol 143:958-969. 2007..To determine the ocular safety of CP-675,206 (Pfizer, New York, New York, USA), a fully human anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody in clinical trials of immunotherapy of metastatic melanoma... - Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccinesRichard C Koya
Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Mol Ther 15:971-80. 2007..Thus, DC precursors can be genetically engineered after a single ex vivo manipulation, resulting in DC vaccines with improved activity... - The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrationsBegona Comin-Anduix
Department of Surgery, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 16:6040-8. 2010..Combining PLX4032 with immunotherapy may allow expanding the durability of responses. The effects of PLX4032 on immune cells were studied to explore the feasibility of future combinatorial approaches with immunotherapy for melanoma... - CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humansRong Rong Huang
Division of Hematology Oncology, 11 934 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Clin Cancer Res 17:4101-9. 2011..A key question is defining whether the intratumoral infiltration (ITI) is a differentiating factor between patients with and without tumor responses... - Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brainRobert M Prins
Department of Surgery, Division of Neurosurgery, David Geffen School of Medicine at UCLA, CHS 74 145, 10833 Le Conte Avenue, PO Box 956901, Los Angeles, CA 90095, USA
Cancer Immunol Immunother 57:1279-89. 2008..These studies demonstrate that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors... - Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockadeAntoni Ribas
Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 15:390-9. 2009..In this study, biopsies of selected accessible tumor lesions from patients treated with tremelimumab were examined to further elucidate the mechanism of its antitumor activity... - Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cellsYu-Pei Liao
Department of Radiation Oncology, Division of Surgical Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
J Immunol 173:2462-9. 2004..1/K(b) transgenic mice. Taken together, these results suggest that radiation modulates MHC class I-mediated antitumor immunity by functionally affecting DC Ag presentation pathways... - Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responsesLana Schumacher
Division of Surgical Oncology, UCLA Medical Center, University of California Los Angeles, USA
J Immunother (1997) 27:191-200. 2004..This study has important implications for the design of DC-based clinical trials... - Immune rejection in a humanized model of murine prostate cancerDorthe Schaue
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1714, USA
Anticancer Res 30:409-14. 2010..Background/Aim: We attempted to develop a humanized mouse model for prostate cancer to study immune recognition and responses to human prostate-tumor antigens in mice... - Enhanced tumor responses to dendritic cells in the absence of CD8-positive cellsAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
J Immunol 172:4762-9. 2004..Elucidation of the signaling events that activate these effective cytotoxic cells and the putative suppressive mechanisms in a wild-type environment may provide means to enhance the clinical activity of DC-based approaches... - The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapyPaul C Tumeh
Division of Hematology Oncology, Department of Medicine, University of California Los Angeles UCLA, Los Angeles, California, USA
J Immunother 33:759-68. 2010.... - Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanomaLynn K Gordon
Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095-7000, USA
Control Clin Trials 25:400-7. 2004..Therefore, surveillance of the eye and vision should be considered in melanoma immunotherapy trials... - Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assaysBegona Comin-Anduix
Department of Surgery, Division of Surgical, University of California at Los Angeles, Los Angeles, California, USA
Clin Cancer Res 12:107-16. 2006..Define an immunologic response using the tetramer and enzyme-linked immunospot (ELISPOT) assays... - Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigenChengyi J Shu
Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, Los Angeles, CA 90095 1662, USA
Int Immunol 21:155-65. 2009..PET may have significant clinical utility by providing the means to quantify anti-tumor T cells throughout the body and provide early correlates for treatment efficacy... - Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responsesRichard C Koya
Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
Proc Natl Acad Sci U S A 107:14286-91. 2010..This approach of TCR engineering and molecular imaging reporter gene labeling is directly translatable to humans and provides useful information on how to clinically develop this mode of therapy... - NK and CD4 cells collaborate to protect against melanoma tumor formation in the brainRobert M Prins
Department of Surgery, Division of Neurosurgery, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
J Immunol 177:8448-55. 2006..Our results suggest that a better understanding of the cross-talk between DC and innate immune cells may provide improved methods to vaccinate patients with tumors located both systemically and within the CNS... - Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trialAntoni Ribas
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA
Clin Cancer Res 17:2987-96. 2011..The goal of this study was to test the safety and activity of a therapeutic vaccine, MKC1106-MT, in patients with metastatic melanoma... - Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell linesErika von Euw
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, Los Angeles, CA, USA
Mol Cancer 11:22. 2012..TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2... - T-cell responses to survivin in cancer patients undergoing radiation therapyDorthe Schaue
Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California 90095 1714, USA
Clin Cancer Res 14:4883-90. 2008..The goal of this study was to determine if radiation therapy (RT) of human cancer enhances or diminishes tumor-specific T-cell reactivity. This is important if immunotherapy is to be harnessed to improve the outcome of cancer radiotherapy... - Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibitionHubing Shi
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Cancer Res 71:5067-74. 2011..Together, our findings offer a rational strategy to guide clinical testing in preidentified subsets of patients who relapse during treatment with (V600E)B-RAF inhibitors... - Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationRamin Nazarian
Division of Dermatology Department of Medicine, UCLA s Jonsson Comprehensive Cancer Center, 52 121 CHS, Los Angeles, California 90095 1750, USA
Nature 468:973-7. 2010.... - Broad antitumor protection by dendritic cells administered to CD8alpha knock out miceAntoni Ribas
Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, 90095, USA
Cancer Immunol Immunother 55:663-71. 2006..3) In sensitive targets a putative activating NK ligand in DC-stimulated NK cells from CD8alphaKO mice signals directly to PI3-K, but is distinct from NKG2D... - Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanomaAntoni Ribas
University of California, 11 934 Factor Building, UCLA Medical Center, Los Angeles, CA 90095 1782, USA
J Transl Med 7:68. 2009..18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune activation at the tumor site and in peripheral blood... - Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanomaBegona Comin-Anduix
Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
J Transl Med 6:22. 2008..CTLA4-blocking antibodies induce tumor regression in a subset of patients with melanoma. Analysis of immune parameters in peripheral blood may help define how responses are mediated... - Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumabAntoni Ribas
Division of Hematology Oncology, Department of Medicine, UCLA, Los Angeles, California, USA
J Nucl Med 51:340-6. 2010..However, there is a paucity of data demonstrating that lymphocyte proliferation does occur in humans treated with CTLA4-blocking antibodies... - T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancerLisa H Butterfield
Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California, USA
Clin Cancer Res 9:5902-8. 2003..We wished to test the hypothesis that AFP peptide-reactive T cells could be expanded in vivo in HCC patients immunized with these four AFP peptides... - Clinical trials with tumor antigen genetically modified dendritic cellsAntoni Ribas
Department of Medicine and Surgery, Division of Hematology Oncology, University of California at Los Angeles, Los Angeles, CA 90095 1782, USA
Semin Oncol 32:556-62. 2005..However, antitumor activity has been marginal thus far. In conclusion, tumor antigen genetically modified DC are a feasible strategy to activate tumor-specific T cells in humans... - Clinical development of the anti-CTLA-4 antibody tremelimumabAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles UCLA, Los Angeles, CA 90095 1782, USA
Semin Oncol 37:450-4. 2010.... - siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomideJonathan E Zuckerman
Division of Hematology Oncology, Department of Medicine, UCLA Medical Center, Los Angeles, California 90095 1782, USA
J Invest Dermatol 131:453-60. 2011..In conclusion, siRNA-mediated RRM2 knockdown significantly inhibits proliferation of melanoma cell lines with different oncogenic mutations with synergistic enhancement in combination with temozolomide... - Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategiesJay Soriano Dela Cruz
Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles (UCLA, Los Angeles, CA 90095, USA
Mol Immunol 43:667-76. 2006.... - Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancerAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California at Los Angeles, Los Angeles, CA, USA
Oncologist 12:873-83. 2007.... - Do we need a different set of response assessment criteria for tumor immunotherapy?Antoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 15:7116-8. 2009..In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria... - A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cellsChao Ma
NanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, California, USA
Nat Med 17:738-43. 2011..The platform represents a new and informative tool for immune monitoring and clinical assessment... - HMGB1 mediates endogenous TLR2 activation and brain tumor regressionJames F Curtin
Department of Medicine, Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America
PLoS Med 6:e10. 2009.... - A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populationsNam T Vu
Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095 1770, USA
J Nucl Med 52:815-21. 2011..This paper demonstrates that the integrated system enables digital control and quantitative measurements of glycolysis in B-Raf(V600E)-mutated melanoma cell lines in response to specific B-Raf inhibition... - CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893Anusha Kalbasi
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, Los Angeles, CA, USA
J Immunother 33:810-6. 2010..Direct exposure to a CD40-activating antibody does not lead to antitumor activity in melanoma cell lines, suggesting that the antitumor effects of these antibodies in the clinic may be indirectly mediated... - Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathwayMohammad Atefi
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, California, United States of America
PLoS ONE 6:e28973. 2011..Clinical trials are in progress using MEK inhibitors following disease progression in patients receiving BRAF inhibitors. However, the PI3K/AKT pathway can also induce resistance to the inhibitors of MAPK pathway... - Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206)Antoni Ribas
Division of Hematology Oncology, 11 934 Factor Building UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, California 90095 1782, USA
Oncologist 13:10-5. 2008..A pivotal phase III trial has also completed accrual; that study compared the overall survival of previously untreated patients receiving single-agent tremelimumab versus dacarbazine or temozolomide... - Therapeutic cancer vaccinesLilah F Morris
Department of Surgery, UCLA Medical Center, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Surg Oncol Clin N Am 16:819-31, ix. 2007..Finally, strategies to directly expand antitumor T lymphocytes and adoptively transfer them to patients with cancer have been developed and shown to induce objective tumor regressions... - Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaBegona Comin-Anduix
Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
PLoS ONE 5:e12711. 2010.... - Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathwayVeerauo V Konkankit
Graduate Program in Physiological Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, 90095, USA
J Transl Med 9:192. 2011..However, the absence of well-characterized, highly immunogenic tumor-rejection antigens (TRA) in gliomas has limited the implementation of targeted immune-based therapies... - BRAF targeted therapy changes the treatment paradigm in melanomaAntoni Ribas
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, and Jonsson Comprehensive Cancer Center at UCLA, 11 934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Nat Rev Clin Oncol 8:426-33. 2011..Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their respective phase I, II, and III trials... - PET imaging of cancer immunotherapyPaul C Tumeh
UCLA, Los Angeles, California, USA
J Nucl Med 49:865-8. 2008..In conclusion, these novel PET-based imaging approaches have demonstrated promise toward the goal of in vivo, noninvasive immune monitoring strategies for evaluating cancer immunotherapy... - Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, CA, USA
J Transl Med 8:39. 2010..In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity... - Metastatic melanoma to the kidney presenting with renal vein tumor thrombusTobias Klatte
Department of Urology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1738, USA
Urology 69:982.e7-9. 2007..The patient later had tumor recurrence at multiple sites. He did not respond to systemic treatment and died 5 months later... - Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanomaLisa H Butterfield
Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA
Clin Cancer Res 9:998-1008. 2003.... - Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cellsDimitrios N Vatakis
Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles CA 90095, USA
Proc Natl Acad Sci U S A 108:E1408-16. 2011..These studies present a potential therapeutic approach and an important tool to understand better and to optimize the human immune response to melanoma and, potentially, to other types of cancer...